Literature DB >> 23150428

Hepatic Cyp2d and Cyp26a1 mRNAs and activities are increased during mouse pregnancy.

Ariel R Topletz1, Huong N Le, Nora Lee, John D Chapman, Edward J Kelly, Joanne Wang, Nina Isoherranen.   

Abstract

There is considerable evidence that drug disposition is altered during human pregnancy and based on probe drug studies, CYP2D6 activity increases during human pregnancy. The aim of this study was to determine whether the changes of CYP2D6 activity observed during human pregnancy could be replicated in the mouse, and explore possible mechanisms of increased CYP2D6 activity during pregnancy. Cyp2d11, Cyp2d22, Cyp2d26 and Cyp2d40 mRNA was increased (P < 0.05) on gestational days (GD) 15 and 19 compared with the non-pregnant controls. There was no change (P > 0.05) in Cyp2d9 and Cyp2d10 mRNA. In agreement with the increased Cyp2d mRNA, Cyp2d-mediated dextrorphan formation from dextromethorphan was increased 2.7-fold (P < 0.05) on GD19 (56.8±39.4 pmol/min/mg protein) when compared with the non-pregnant controls (20.8±11.2 pmol/min/mg protein). An increase in Cyp26a1 mRNA (10-fold) and retinoic acid receptor (Rar)β mRNA (2.8-fold) was also observed during pregnancy. The increase in Cyp26a1 and Rarβ mRNA during pregnancy indicates increased retinoic acid signaling in the liver during pregnancy. A putative retinoic acid response element was identified within the Cyp2d40 promoter and the mRNA of Cyp2d40 correlated (P < 0.05) with Cyp26a1 and Rarβ. These results show that Cyp2d mRNA is increased during mouse pregnancy the and mouse may provide a suitable model to investigate the mechanisms underlying the increased clearance of CYP2D6 probes observed during human pregnancy. Our findings also suggest that retinoic acid signaling in the liver is increased during pregnancy, which may have broader implications to energy homeostasis in the liver during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23150428      PMCID: PMC3558865          DOI: 10.1124/dmd.112.049379

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  39 in total

1.  4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7.

Authors:  V M Samokyszyn; W E Gall; G Zawada; M A Freyaldenhoven; G Chen; P I Mackenzie; T R Tephly; A Radominska-Pandya
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

2.  Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting.

Authors:  R Jover; R Bort; M J Gómez-Lechón; J V Castell
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

3.  The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.

Authors:  J Corchero; C P Granvil; T E Akiyama; G P Hayhurst; S Pimprale; L Feigenbaum; J R Idle; F J Gonzalez
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

4.  Cytochrome P450RAI(CYP26) promoter: a distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism.

Authors:  O Loudig; C Babichuk; J White; S Abu-Abed; C Mueller; M Petkovich
Journal:  Mol Endocrinol       Date:  2000-09

5.  Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population.

Authors:  Douglas D Glover; Mayur Amonkar; Blanche F Rybeck; Timothy S Tracy
Journal:  Am J Obstet Gynecol       Date:  2003-04       Impact factor: 8.661

6.  Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation.

Authors:  Joseph A Carcillo; Adedayo Adedoyin; Gilbert J Burckart; Reginald F Frye; Raman Venkataramanan; Carmela Knoll; Kenneth Thummel; Lorin Roskos; John W Wilson; Susan Sereika; Marjorie Romkes; Zourab Bebia; Robert A Branch
Journal:  Clin Pharmacol Ther       Date:  2003-05       Impact factor: 6.875

7.  Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.

Authors:  Justin D Lutz; Vaishali Dixit; Catherine K Yeung; Leslie J Dickmann; Alex Zelter; Jayne E Thatcher; Wendel L Nelson; Nina Isoherranen
Journal:  Biochem Pharmacol       Date:  2008-10-17       Impact factor: 5.858

8.  The mechanism causing the difference in kinetic properties between rat CYP2D4 and human CYP2D6 in the oxidation of dextromethorphan and bufuralol.

Authors:  Shizuo Narimatsu; Daichi Kazamori; Kazufumi Masuda; Takashi Katsu; Yoshihiko Funae; Shinsaku Naito; Hironori Nakura; Shigeru Yamano; Nobumitsu Hanioka
Journal:  Biochem Pharmacol       Date:  2008-11-17       Impact factor: 5.858

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  The role of vitamin A in mammalian reproduction and embryonic development.

Authors:  Margaret Clagett-Dame; Hector F DeLuca
Journal:  Annu Rev Nutr       Date:  2002       Impact factor: 11.848

View more
  6 in total

1.  Repression of multiple CYP2D genes in mouse primary hepatocytes with a single siRNA construct.

Authors:  Omaima Elraghy; William S Baldwin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-08-15       Impact factor: 2.416

2.  Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice.

Authors:  Kwi Hye Koh; Xian Pan; Hong-Wu Shen; Samuel L M Arnold; Ai-Ming Yu; Frank J Gonzalez; Nina Isoherranen; Hyunyoung Jeong
Journal:  J Biol Chem       Date:  2013-12-06       Impact factor: 5.157

3.  In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.

Authors:  Jennifer E Sager; Sasmita Tripathy; Lauren S L Price; Abhinav Nath; Justine Chang; Alyssa Stephenson-Famy; Nina Isoherranen
Journal:  Biochem Pharmacol       Date:  2016-11-09       Impact factor: 5.858

4.  Hepatocyte nuclear factor (HNF) 4α transactivation of cytochrome P450 (Cyp) 2d40 promoter is enhanced during pregnancy in mice.

Authors:  Miaoran Ning; Kwi Hye Koh; Xian Pan; Hyunyoung Jeong
Journal:  Biochem Pharmacol       Date:  2015-01-15       Impact factor: 5.858

5.  Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

Authors:  Nina Isoherranen; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2013-02       Impact factor: 3.922

6.  Returning to tricyclic antidepressants for depression during childbearing: clinical and dosing challenges.

Authors:  Lauren M Osborne; Catherine A Birndorf; Lauren E Szkodny; Katherine L Wisner
Journal:  Arch Womens Ment Health       Date:  2014-03-26       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.